NEW YORK, June 20, 2022 /PRNewswire/ -- Attention Spero Therapeutics, Inc. ("Spero") (NASDAQ: SPRO) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between October 28, 2021 and May 2, 2022.
If you suffered a loss on your investment in Spero, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=28745&wire=4
ABOUT THE ACTION: The class action against Spero includes allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: July 25, 2022
Aggrieved Spero investors only have until July 25, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:https://www.prnewswire.com/news-releases/class-action-alert-the-law-offices-of-vincent-wong-remind-spero-investors-of-a-lead-plaintiff-deadline-of-july-25-2022-301570434.html
SOURCE The Law Offices of Vincent Wong
